博雲新材(002297.SZ):近年啟動博雲東方麓谷基地產業化項目的投資建設,目前該項目已基本完成工程建設
格隆匯10月13日丨博雲新材(002297.SZ)在10月12日接受特定對象調研時表示,公司目前主要是通過內生增長來推動各項業務發展,2021年、2022年公司營業收入保持了較高增速,在航空航天方面,隨着市場需求增加,公司近幾年通過自有資金投入擴大了部分產品的生產能力。在硬質合金業務方面,受限於原有生產車間的產能不足,公司近年啟動了博雲東方麓谷基地產業化項目的投資建設,目前該項目已基本完成工程建設,正在進行部分設備的安裝調試以及試生產,預計2024年將完成主要生產設備的投入,隨着該項目的投入使用,將會較大提升公司硬質合金產品的生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.